Post on 04-Apr-2018
transcript
7/30/2019 Oncology - Osteosarcoma v2
1/48
- , .
(,, )
- , , , , .
7/30/2019 Oncology - Osteosarcoma v2
2/48
2007
1,6%.
2007
1,8%.
7/30/2019 Oncology - Osteosarcoma v2
3/48
2
:
- ,
;
,
, .
7/30/2019 Oncology - Osteosarcoma v2
4/48
, ,
.
( , ,
, , ,, ),
. 36
, 17 .
7/30/2019 Oncology - Osteosarcoma v2
5/48
. 2007 1950
.
0,48%, 0,33%
.
7/30/2019 Oncology - Osteosarcoma v2
6/48
, ;
10%
.
.
- .
7/30/2019 Oncology - Osteosarcoma v2
7/48
- - 77%.
. .
- 21% .
, .
7/30/2019 Oncology - Osteosarcoma v2
8/48
.....1%
3%
....96%
7/30/2019 Oncology - Osteosarcoma v2
9/48
:
1. ;
2. ;3. ;
4. .
7/30/2019 Oncology - Osteosarcoma v2
10/48
1. . : , -,
.
: , .
2. .
: , ,, .
: ,
, .
3. ().
7/30/2019 Oncology - Osteosarcoma v2
11/48
4. - : ,
,.5. .: , ,
: ,
.: .6. .
: ,
.: , ,
,
.
7/30/2019 Oncology - Osteosarcoma v2
12/48
7. .
, ,
, .
8. .9. :
, ,
,
, , , "
", " "
7/30/2019 Oncology - Osteosarcoma v2
13/48
:
1. 20-45%
2. 10-20%
3. 10-15%
,
.
7/30/2019 Oncology - Osteosarcoma v2
14/48
- ,
80%
4
45%
2-3
6
7/30/2019 Oncology - Osteosarcoma v2
15/48
,
15-20% .
.
2
:
1. /- 20%,
2. - 21%, -10%
3. - 11%, 14%
4. : - 7%, - 5%,- 4% 2%.
7/30/2019 Oncology - Osteosarcoma v2
16/48
,
.
,
30
.
7/30/2019 Oncology - Osteosarcoma v2
17/48
()
0
1 8
2 > 8
3
(N)
N
N0
N1
()
0
1
1b
7/30/2019 Oncology - Osteosarcoma v2
18/48
G (grade) -
G
G1
G2 G3
G4
7/30/2019 Oncology - Osteosarcoma v2
19/48
I G1-2 T1 N0, NX M0 I G1-2 T2 N0, NX M0
II G3-4 T1 N0, NX M0
II G3-4 2 N0, NX M0
III G 3 N0, NX M0
IV G N0, NX M1a
IV G N1 M
G N M1b
7/30/2019 Oncology - Osteosarcoma v2
20/48
,
,
,
,
,
.
7/30/2019 Oncology - Osteosarcoma v2
21/48
, .
( 80%), , 30%
.
(10%), .
710% .
7/30/2019 Oncology - Osteosarcoma v2
22/48
-
.
:
,
- (),
:, , , , ( G),
.
7/30/2019 Oncology - Osteosarcoma v2
23/48
, .
7/30/2019 Oncology - Osteosarcoma v2
24/48
7/30/2019 Oncology - Osteosarcoma v2
25/48
.
7/30/2019 Oncology - Osteosarcoma v2
26/48
-
7/30/2019 Oncology - Osteosarcoma v2
27/48
7/30/2019 Oncology - Osteosarcoma v2
28/48
, L2
7/30/2019 Oncology - Osteosarcoma v2
29/48
,
.
7/30/2019 Oncology - Osteosarcoma v2
30/48
- ()
7/30/2019 Oncology - Osteosarcoma v2
31/48
7/30/2019 Oncology - Osteosarcoma v2
32/48
7/30/2019 Oncology - Osteosarcoma v2
33/48
7/30/2019 Oncology - Osteosarcoma v2
34/48
(
),
7/30/2019 Oncology - Osteosarcoma v2
35/48
7/30/2019 Oncology - Osteosarcoma v2
36/48
7/30/2019 Oncology - Osteosarcoma v2
37/48
7/30/2019 Oncology - Osteosarcoma v2
38/48
7/30/2019 Oncology - Osteosarcoma v2
39/48
7/30/2019 Oncology - Osteosarcoma v2
40/48
,
7/30/2019 Oncology - Osteosarcoma v2
41/48
().
7/30/2019 Oncology - Osteosarcoma v2
42/48
( , -) ,
50-60 , .
.
7/30/2019 Oncology - Osteosarcoma v2
43/48
,
,
,
/
7/30/2019 Oncology - Osteosarcoma v2
44/48
-
+
+ +
+
/
+ -
7/30/2019 Oncology - Osteosarcoma v2
45/48
- :
1.
2. ,3.
4.
5.
:+,
+.
7/30/2019 Oncology - Osteosarcoma v2
46/48
,
,
7/30/2019 Oncology - Osteosarcoma v2
47/48
7/30/2019 Oncology - Osteosarcoma v2
48/48
, 12%.
5%.
60%,